Diagnostic Performance of Fas Ligand mRNA Expression for Acute Rejection after Kidney Transplantation: A Systematic Review and Meta-Analysis.
BACKGROUND
The value of Fas ligand (FASL) as a diagnostic immune marker for acute renal rejection is controversial; this meta-analysis aimed to clarify the role of FASL in acute renal rejection.


METHODS
The relevant literature was included by systematic searching the MEDLINE, EMBASE, and Cochrane Library databases. Accuracy data for acute rejection (AR) and potential confounding variables (the year of publication, area, sample source, quantitative techniques, housekeeping genes, fluorescence staining, sample collection time post-renal transplantation, and clinical classification of AR) were extracted after carefully reviewing the studies. Data were analyzed by Meta-DiSc 1.4, RevMan 5.0, and the Midas module in Stata 11.0 software.


RESULTS
Twelve relevant studies involving 496 subjects were included. The overall pooled sensitivity, specificity, positive likelihood ratio (LR), negative LR, and diagnostic odds ratio, together with the 95% CI were 0.64 (0.57-0.70), 0.90 (0.85-0.93), 5.66 (3.51-9.11), 0.30 (0.16-0.54), and 30.63 (14.67-63.92), respectively. The area under the summary receiver operating characteristic curve (AUC) was 0.9389. Fagan's nomogram showed that the probability of AR episodes in the kidney transplant recipient increased from 15% to 69% when FASL was positive, and was reduced to 4% when FASL was negative. No threshold effect, sensitivity analyses, meta-regression, and subgroup analyses based on the potential variables had a significant statistical change for heterogeneity.


CONCLUSIONS
Current evidence suggests the diagnostic potential for FASL mRNA detection as a reliable immune marker for AR in renal allograft recipients. Further large, multicenter, prospective studies are needed to validate the power of this test marker in the non-invasive diagnosis of AR after renal transplantation.
Department of Urology, the First Affiliated Hospital of Jinan University, Guangzhou, China.
Baoli
B
Heng
Department of Urology, the First Affiliated Hospital of Jinan University, Guangzhou, China.
Hongwen
H
Ding
Department of Urology, the First Affiliated Hospital of Jinan University, Guangzhou, China.
Haolin
H
Ren
Department of Urology, the First Affiliated Hospital of Jinan University, Guangzhou, China.
Liping
L
Shi
Department of Urology, the First Affiliated Hospital of Jinan University, Guangzhou, China.
Jie
J
Chen
Department of Urology, the First Affiliated Hospital of Jinan University, Guangzhou, China.
Xun
X
Wu
Department of Urology, the First Affiliated Hospital of Jinan University, Guangzhou, China.
Caiyong
C
Lai
Department of Urology, the First Affiliated Hospital of Jinan University, Guangzhou, China.
Ganshen
G
Yu
Department of Urology, the First Affiliated Hospital of Jinan University, Guangzhou, China.
Yin
Y
Xu
Department of Urology, the First Affiliated Hospital of Jinan University, Guangzhou, China.
Zexuan
Z
Su
D015415:Biomarkers; D053222:Fas Ligand Protein / Q000235:genetics* / Q000378:metabolism* / Q000652:urine; D006084:Graft Rejection / Q000235:genetics* / Q000276:immunology*; D053804:Granzymes / Q000378:metabolism; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects*; D054353:Perforin / Q000378:metabolism; D011379:Prognosis; D012333:RNA, Messenger / Q000096:biosynthesis* / Q000235:genetics; D012372:ROC Curve
D015415:Biomarkers; C505661:FASLG protein, human; D053222:Fas Ligand Protein; D012333:RNA, Messenger; D054353:Perforin; D053804:Granzymes